Recursion Pharmaceuticals Hits Day Low of $3.27 Amid Price Pressure

Recursion Pharmaceuticals, Inc. experienced a significant decline in its stock performance today, with a drop of 7.3%. The stock reached an intraday low of USD 3.27, reflecting ongoing challenges for the small-cap company within the Pharmaceuticals & Biotechnology sector. Over the past week, Recursion has seen a notable decrease of 16.67%, while its performance over the past year has been marked by a substantial decline of 37.5%. Year-to-date, the stock has lost 19.32%, contrasting sharply with the S&P 500, which has gained 9.79% during the same period. The company's financial metrics indicate a challenging landscape, with a return on equity of -57.01% and a price-to-book ratio of 1.37. Additionally, Recursion's profits have decreased by 39.1% over the past year, contributing to its consistent underperformance against the S&P 500 over the last three years. As the company navigates these financial hurdles, its market capitalization stands at USD 1,553 million.